Lawyers representing researchers, pathologists, and women’s health groups urged a federal appeals court in Washington, D.C., to uphold a ruling that said a genetics company’s patents on two human genes are invalid and unconstitutional.
For more than an hour on April 4, the U.S. Court of Appeals for the Federal Circuit grappled with the case, narrowly assessing whether an isolated gene is substantively different from DNA itself, and more broadly looking at how the resolution of the case has potential consequences for the biotechnology industry.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
